Mesoblast, an Australia-listed regenerative medicine company, has raised A$170m ($150m) in a private placement of shares including to its “existing strategic investors”. Under the placement, 27 million ordinary shares, 9.4%, were issued at A$6.30 each, a discount of 2.2% to the closing price of the company’s shares on 1 March. However, Mesoblast’s spokeswoman by email…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
